Controlled release of tetracycline hydrochloride from poly (omega-pentadecalactone-co-epsilon-caprolactone)/gelatin nanofibers


Ülker Turan C., Yılmazer Metin A., Guvenilir Y.

EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, cilt.162, ss.59-69, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 162
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1016/j.ejpb.2021.02.009
  • Dergi Adı: EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Aquatic Science & Fisheries Abstracts (ASFA), BIOSIS, Biotechnology Research Abstracts, CAB Abstracts, EMBASE, International Pharmaceutical Abstracts, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.59-69
  • İstanbul Teknik Üniversitesi Adresli: Evet

Özet

Development of drug delivery systems is an extensively researched area in biomedical field. In recent years, there is an increasing interest on fabrication of biocompatible nanofibrous drug delivery systems. In the present study, poly(?-pentadecalactone-co-?-caprolactone)/gelatin nanofibrous membranes were fabricated for the controlled delivery and release of tetracycline hydrochloride (TCH) antibiotic. Poly(?-pentadecalactone-co-?-caprolactone) content provides an originality to the membrane, since it has been synthesized enzymatically previously. Varied amounts of tetracycline hydrochloride including poly(?-pentadecalactone-co-?-caprolactone)/gelatin (1:1, v:v) binary polymer blend was electrospun and characterizations (morphological and molecular structure, wettability characteristics, and thermal behavior) were applied to investigate the incorporation of drug molecule. Afterwards, in vitro drug release studies were carried out and mathematical modelling was applied to drug release data in order to clarify the transport mechanism of drug. TCH release profile comprised of an initial burst release in first hour and followed by a sustained release through 14 days which allowed sufficient antibacterial activity against both Gram-negative (Escherichia coli) and Gram-positive (Staphylococcus aureus and Bacillus subtilis) bacteria. The presented drug delivery system may be applied as an antibacterial wound dressing device for skin infections.